Dynavax Technologies Corporation news

   Watch this stock
Showing stories 1 - 5 of about 5   

Articles published

DVAX 21.05 -0.94 (-4.27%)
price chart
Dynavax Gets Crushed After Advisory Committee Vote
In after-hours trading, we saw an enormous drop in shares of Dynavax (Nasdaq: DVAX) that caught my attention due to the severity of the drop and the huge amount of fuss over the incident.
Dynavax Falls After Vaccine Fails to Win Panel Backing  Bloomberg
Despite Safety Concerns, Dynavax's Heplisav Should Receive FDA Approval
On November 15, 2012, the FDA will hold an advisory committee meeting for Dynavax's (DVAX) Heplisav, an investigational vaccine for all known subtypes of hepatitis B virus (HBV).
Dynavax's Heplisav Vaccine Works on Hepatitis B, FDA Says
Dynavax Technologies Corp.'s Heplisav vaccine works against the contagious liver disease hepatitis B, Food and Drug Administration staff said.
Can Dynavax overcome Heplisav blow?
Two weeks ago, an FDA panel dealt a blow to Dynavax Technologies ($DVAX), raising concerns about the safety of the company's hepatitis B vaccine, Heplisav.
European Stocks Drop; Yen Weakens to Six-Month Low
Dynavax Technologies Corp. slid 47 percent after its hepatitis B vaccine failed to win the backing of U.S. regulatory advisers.